

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2030

Market Report | 2024-09-17 | 291 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The Human Microbiome market is expected to reach USD 4,206.0 million in 2030 from USD 814.6 million in 2024, at a CAGR of 31.5% during the forecast period.

Factors such as the collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine are driving the growth of the Human Microbiome market. However, complex regulatory policies adversely impact the commercialization of microbiomes, restraining market growth.

"The probiotics segment accounted for the largest share by product segment in the human microbiome market in 2023."

The market is analyzed across four key products: drugs, probiotics, prebiotics, and synbiotics. The segment with the biggest share in the Human Microbiome market in 2023 is Probiotics, Driven by increasing consumer awareness about the benefits of probiotics for gut health, immunity, and overall wellness. Still, the Prebiotics segment held the second-largest market share. Additionally, widespread consumer demand and acceptance as health supplements along with active research supporting health claims on probiotics supports the segment growth. The market is also propelled by the growing popularity of functional foods and beverages containing probiotics.

"The Asia Pacific region is growing at the highest CAGR in the human microbiome market from 2024 to 2030."

The Asia Pacific is estimated to be the fastest-growing segment of the market primarily due to the increasing awareness of microbiome health, emerging healthcare and biotechnology industries, government support, and funding potential for personalized medicine. The development of high - throughput sequencing technologies has made it possible to sequence the entire microbiome in a single sample, enabling researchers to more accurately and comprehensively characterize the microbial

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

communities that are present in samples. Challenges in terms of data protection and privacy, as well as high cost of human microbiomes, are expected to restrain the growth of the Asia-Pacific market. In addition, there may be cultural and linguistic barriers to adoption in certain regions, as well as concerns about the accuracy and clinical utility of microbiome sequencing data.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Executives - 25%, CXOs - 30%, and Managers - 45%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, Middle East & Africa -5%..

List of Companies Profiled in the Report:

- Nestle S.A. (Switzerland)
- Ferring Pharmaceuticals (Switzerland)
- BiomeBank (Australia)
- Seed Health, Inc. (US)
- International Flavors & Fragrances Inc (US)
- Pendulum (US)
- BioHM Health Inc. (US)
- Actial Farmaceutica SRL (Italy)
- Optibiotix Health plc (UK)
- Resbiotic (US)
- Infinant Health Inc (US)
- Biogaia AB (Sweden)
- Exegi Pharma LLC (US)

Research Coverage:

This research report categorizes the Human Microbiome market by Product (Drugs, Probiotics, Prebiotics, and others), Disease (Infectious disease, Gastrointestinal Disease, Endocrine, and metabolic disorders, Cancer, and Other Diseases), Type (Bacterial Consortia Transplantation (BCT)/ Fecal Microbiota Transplantation (FMT), Peptides, Live Biotherapeutic Products, and Others) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Human Microbiome market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the Human Microbiome market. Competitive analysis of top players and upcoming startups in the Human Microbiome market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Human Microbiome market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The report provides insights on the following pointers:

Analysis of key drivers (Collaborative initiatives between organizations, academia, and the microbiome industry, Increase in the number of Start-Ups,/SMEs exploring the microbiome niche, Advancements in microbiome sequencing), restraints (Adverse impact of complex regulatory policies on commercialization of microbiomes, High investment in commercialization of microbiome drugs), opportunities (Increase in demand for personalized medicine, and Emergence of synbiotics), and challenges (Slow patient adoption of microbiome-based therapies and Complexities involved in development of microbiome therapies) influencing the growth of the market.

-□Product Development/Innovation: Detailed insights on newly launched products of the Human Microbiome market

-□Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

-□Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the Human Microbiome market

-□Competitive Assessment: Nestle S.A. (Switzerland), Ferring Pharmaceuticals (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc (US), Pendulum (US), BioHM Health Inc. (US), Actial Farmaceutica SRL (Italy), Optibiotix Health plc (UK), Resbiotic (US), Infinit Health Inc (US), Biogaia AB (Sweden), and Exegi Pharma Llc (US) among others in the market.

Table of Contents:

1□INTRODUCTION□	29
1.1□STUDY OBJECTIVES□	29
1.2□MARKET DEFINITION□	29
1.2.1□INCLUSIONS & EXCLUSIONS□	30
1.3□STUDY SCOPE□	30
1.3.1□MARKET SEGMENTATION□	30
1.4□YEARS CONSIDERED□	31
1.5□CURRENCY□	31
1.6□RESEARCH LIMITATIONS□	31
1.7□STAKEHOLDERS□	31
1.8□SUMMARY OF CHANGES□	32
1.9□IMPACT OF AI/GEN AI□	32
2□RESEARCH METHODOLOGY□	33
2.1□RESEARCH DATA□	33
2.1.1□SECONDARY DATA□	34
2.1.2□PRIMARY DATA□	35
2.2□MARKET ESTIMATION METHODOLOGY□	36
2.2.1□MARKET ESTIMATION□	36
2.2.1.1□Insights of primary experts□	38
2.2.2□SEGMENTAL MARKET SIZE ESTIMATIONS□	39
2.3□MARKET GROWTH RATE PROJECTIONS□	40
2.4□MARKET BREAKDOWN & DATA TRIANGULATION□	42
2.5□RESEARCH ASSUMPTIONS□	43
2.6□LIMITATIONS□	43
2.7□RISK ANALYSIS□	43
3□EXECUTIVE SUMMARY□	44
4□PREMIUM INSIGHTS□	48
4.1□HUMAN MICROBIOME MARKET OVERVIEW□	48
4.2□NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT AND COUNTRY (2023)□	49
4.3□HUMAN MICROBIOME MARKET, BY TYPE (2023 VS. 2030)□	49

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

?

5	MARKET OVERVIEW	50
5.1	INTRODUCTION	50
5.2	MARKET DYNAMICS	50
5.2.1	DRIVERS	51
5.2.1.1	Collaborative initiatives between organizations and academia in microbiome industry	51
5.2.1.2	Increasing number of start-ups/SMEs exploring microbiome niche	53
5.2.1.3	Advancements in microbiome sequencing	54
5.2.2	RESTRAINTS	54
5.2.2.1	Adverse impact of complex regulatory policies on commercialization of microbiomes	54
5.2.2.2	High investments in commercialization of microbiome drugs	56
5.2.3	OPPORTUNITIES	56
5.2.3.1	Increasing demand for personalized medicine	56
5.2.3.2	Emergence of postbiotics	57
5.2.4	CHALLENGES	57
5.2.4.1	Slow patient adoption of microbiome-based therapies	57
5.2.4.2	Complexities involved in development of microbiome therapies	58
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	58
5.4	PRICING ANALYSIS	59
5.4.1	AVERAGE SELLING PRICE OF HUMAN MICROBIOME DRUGS, BY KEY PLAYER	59
5.4.2	AVERAGE COST RANGE OF HUMAN MICROBIOME PRODUCTS, 2021-2023	60
5.4.3	AVERAGE SELLING PRICE ANALYSIS, BY REGION	61
5.5	PIPELINE ANALYSIS	62
5.6	PATENT ANALYSIS	64
5.7	ECOSYSTEM ANALYSIS	65
5.8	SUPPLY CHAIN ANALYSIS	66
5.9	VALUE CHAIN ANALYSIS	67
5.10	IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET	68
5.11	TECHNOLOGY ANALYSIS	70
5.11.1	KEY TECHNOLOGIES	70
5.11.1.1	Whole-genome sequencing	70
5.11.1.2	16s RNA sequencing method	71
5.11.1.3	Nanopore sequencing	71
5.11.2	COMPLEMENTARY TECHNOLOGIES	71
5.11.2.1	Metatranscriptomics	71
5.11.2.2	Metagenomics	72
5.11.2.3	Metabolomics	72
5.11.3	ADJACENT TECHNOLOGIES	73
5.11.3.1	Sample preparation	73
5.11.3.2	Data analysis	73
5.11.3.3	Library synthesis	73
5.12	KEY CONFERENCES & EVENTS IN 2024-2025	74
5.13	REGULATORY ANALYSIS	76
5.13.1	REGULATORY LANDSCAPE	76
5.13.1.1	North America	76
5.13.1.2	Europe	77
5.13.1.3	Asia Pacific	78

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.13.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	81
5.14	PORTER'S FIVE FORCES ANALYSIS	84
5.14.1	THREAT OF NEW ENTRANTS	85
5.14.2	THREAT OF SUBSTITUTES	85
5.14.3	BARGAINING POWER OF BUYERS	86
5.14.4	BARGAINING POWER OF SUPPLIERS	86
5.14.5	INTENSITY OF COMPETITIVE RIVALRY	86
5.15	KEY STAKEHOLDERS & BUYING CRITERIA	87
5.15.1	KEY STAKEHOLDERS IN BUYING PROCESS	87
5.15.2	BUYING CRITERIA	88
5.16	CASE STUDY ANALYSIS	88
5.16.1	EFFECT OF REBYOTA ON QUALITY OF LIFE IN PATIENTS WITH RECURRENT CLOSTRIDIODES DIFFICILE INFECTION	88
5.16.2	ECOSPOR IV STUDY OF VOWST FOR CLOSTRIDIODES DIFFICILE INFECTION	88
5.16.3	DELONG#3 STUDY FOR QUALITY OF LIFE IMPROVEMENT BY VSL#3 PROBIOTIC IN POST-COVID-19 PATIENTS.	89
5.17	INVESTMENT & FUNDING SCENARIO	89
5.17.1	OTHER INVESTMENTS AND FUNDING	93
6	HUMAN MICROBIOME MARKET, BY PRODUCT	95
6.1	INTRODUCTION	96
6.2	DRUGS	96
6.2.1	GROWING PIPELINE OF MICROBIOME-BASED DRUGS IN LATE-STAGE CLINICAL TRIALS TO DRIVE MARKET	96
6.3	PROBIOTICS	97
6.3.1	GROWING CONSUMER AWARENESS ABOUT PROBIOTICS FOR IMPROVED GUT HEALTH AND IMMUNITY TO AID MARKET GROWTH	97
6.4	PREBIOTICS	100
6.4.1	DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH	100
6.5	SYNBIOTICS	103
6.5.1	GROWING DEMAND FOR PERSONALIZED TREATMENT AND RISING INCIDENCE OF DYSBIOSIS TO AUGMENT MARKET GROWTH	103
7	HUMAN MICROBIOME MARKET, BY DISEASE	106
7.1	INTRODUCTION	107
7.2	INFECTIOUS DISEASES	107
7.2.1	EMERGENCE OF MULTI-DRUG-RESISTANT BACTERIA TO BOOST MARKET GROWTH	107
7.3	GASTROINTESTINAL DISEASES	109
7.3.1	INCREASING DEMAND FOR PERSONALIZED THERAPIES TO PROPEL MARKET GROWTH	109
7.4	ENDOCRINE & METABOLIC DISORDERS	111
7.4.1	DEVELOPMENT OF MICROBIOME MODULATORS FOR METABOLIC DISORDERS TO BOOST MARKET GROWTH	111
7.5	OTHER DISEASES	115
8	HUMAN MICROBIOME MARKET, BY TYPE	118
8.1	INTRODUCTION	119
8.2	BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)	119
8.2.1	ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH	119
8.3	LIVE BIOTHERAPEUTIC PRODUCTS (LBP)	122
8.3.1	GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET	122
8.4	OTHER MICROBIOME TYPES	125
9	HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION	129

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.1	INTRODUCTION	130
9.2	ORAL ROUTE OF ADMINISTRATION	130
9.2.1	WIDESPREAD PATIENT ACCEPTANCE AND EXTENSIVE PRODUCT OFFERINGS TO DRIVE MARKET GROWTH	130
9.3	RECTAL ROUTE OF ADMINISTRATION	133
9.3.1	PRODUCT APPROVALS AND EFFICACY IN TARGETED DELIVERY TO SUPPORT MARKET GROWTH	133
10	HUMAN MICROBIOME MARKET, BY END USER	136
10.1	INTRODUCTION	137
10.2	HOSPITALS & CLINICS	137
10.2.1	AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT MARKET GROWTH	137
10.3	LONG-TERM CARE FACILITIES	140
10.3.1	SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET	140
10.4	OTHER END USERS	143
	?	
11	HUMAN MICROBIOME MARKET, BY REGION	146
11.1	INTRODUCTION	147
11.2	NORTH AMERICA	147
11.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	150
11.2.2	US	151
11.2.2.1	Strong ecosystem backed by regulation, research, and funding to drive market	151
11.2.3	CANADA	153
11.2.3.1	Government initiatives, independent organizations, and academia collaborations to boost microbiome research	153
11.3	EUROPE	156
11.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	158
11.3.2	GERMANY	159
11.3.2.1	Rapid increase in government and private funding to propel market	159
11.3.3	UK	161
11.3.3.1	Significant government investments in microbiome research and presence of microbiome companies to propel growth	161
11.3.4	FRANCE	163
11.3.4.1	Growing awareness and rise of specialized organizations to boost growth	163
11.3.5	ITALY	166
11.3.5.1	Government intervention and academic institutions to drive market growth	166
11.3.6	SPAIN	168
11.3.6.1	Growing academic research initiatives to boost growth	168
11.3.7	REST OF EUROPE	170
11.4	ASIA PACIFIC	172
11.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	175
11.4.2	CHINA	176
11.4.2.1	Increasing R&D investments to drive growth	176
11.4.3	JAPAN	178
11.4.3.1	Growing geriatric population to present opportunities for market growth	178
11.4.4	INDIA	181

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.4.4.1	Increasing prevalence of chronic diseases to support growth	181
11.4.5	SOUTH KOREA	183
11.4.5.1	Increasing prevalence of chronic diseases to support growth	183
11.4.6	AUSTRALIA	185
11.4.6.1	Growing number of product approvals to boost growth	185
11.4.7	REST OF ASIA PACIFIC	187
	?	
11.5	LATIN AMERICA	189
11.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	191
11.5.2	BRAZIL	192
11.5.2.1	Rising probiotics demand to drive market	192
11.5.3	REST OF LATIN AMERICA	194
11.6	MIDDLE EAST	196
11.6.1	MACROECONOMIC OUTLOOK IN MIDDLE EAST	198
11.6.2	GCC COUNTRIES	199
11.6.2.1	Saudi Arabia	201
11.6.2.1.1	Increasing focus on R&D to boost market growth	201
11.6.2.2	UAE	203
11.6.2.2.1	Increasing focus on R&D and healthcare spending to boost market growth	203
11.6.2.3	Rest of GCC countries	205
11.6.3	REST OF MIDDLE EAST	207
11.7	AFRICA	209
11.7.1	STUDIES AND INITIATIVES TO BOOST MARKET GROWTH	209
11.7.2	MACROECONOMIC OUTLOOK FOR AFRICA	211
12	COMPETITIVE LANDSCAPE	213
12.1	INTRODUCTION	213
12.1.1	KEY PLAYER STRATEGY/RIGHT TO WIN	213
12.1.2	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET	213
12.2	REVENUE ANALYSIS, 2021-2023	215
12.3	MARKET SHARE ANALYSIS, 2023	217
12.4	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	220
12.4.1	STARS	220
12.4.2	EMERGING LEADERS	220
12.4.3	PERVASIVE PLAYERS	220
12.4.4	PARTICIPANTS	220
12.4.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	222
12.4.5.1	Company footprint	222
12.4.5.2	Product footprint	223
12.4.5.3	Type footprint	224
12.4.5.4	Disease footprint	225
12.4.5.5	Region footprint	226
12.5	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	226
12.5.1	PROGRESSIVE COMPANIES	226
12.5.2	RESPONSIVE COMPANIES	226
12.5.3	DYNAMIC COMPANIES	227
12.5.4	STARTING BLOCKS	227

12.5.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	228
12.6	COMPANY VALUATION & FINANCIAL METRICS	230
12.7	BRAND/PRODUCT COMPARISON	231
12.8	COMPETITIVE SCENARIO	233
12.8.1	PRODUCT APPROVALS	233
12.8.2	DEALS	234
13	COMPANY PROFILES	235
13.1	KEY PLAYERS	235
13.1.1	INTERNATIONAL FLAVORS & FRAGRANCES, INC.	235
13.1.1.1	Business overview	235
13.1.1.2	Products offered	236
13.1.1.3	Recent developments	238
13.1.1.3.1	Deals	238
13.1.1.4	MnM view	239
13.1.1.4.1	Key strengths	239
13.1.1.4.2	Strategic choices	239
13.1.1.4.3	Weaknesses & competitive threats	239
13.1.2	SEED HEALTH, INC.	240
13.1.2.1	Business overview	240
13.1.2.2	Products offered	240
13.1.2.3	Recent developments	241
13.1.2.3.1	Deals	241
13.1.2.4	MnM view	242
13.1.2.4.1	Key strengths	242
13.1.2.4.2	Strategic choices	242
13.1.2.4.3	Weaknesses & competitive threats	242
13.1.3	PENDULUM	243
13.1.3.1	Business overview	243
13.1.3.2	Products offered	244
13.1.3.3	Recent developments	244
13.1.3.3.1	Deals	244
13.1.3.4	MnM view	245
13.1.3.4.1	Key strengths	245
13.1.3.4.2	Strategic choices	245
13.1.3.4.3	Weaknesses & competitive threats	245
13.1.4	SERES THERAPEUTICS	246
13.1.4.1	Business overview	246
13.1.4.2	Products offered	247
13.1.4.3	Recent developments	247
13.1.4.3.1	Product approvals	247
13.1.4.3.2	Deals	248
?		
13.1.4.4	MnM view	249
13.1.4.4.1	Key strengths	249
13.1.4.4.2	Strategic choices	249
13.1.4.4.3	Weaknesses & competitive threats	249
13.1.5	FERRING PHARMACEUTICALS	250

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.1.5.1	Business overview	250
13.1.5.2	Products offered	251
13.1.5.3	Recent developments	252
13.1.5.3.1	Product approvals	252
13.1.5.3.2	Deals	252
13.1.5.4	MnM view	253
13.1.5.4.1	Key strengths	253
13.1.5.4.2	Strategic choices	253
13.1.5.4.3	Weaknesses & competitive threats	253
13.1.6	BIOMEBANK	254
13.1.6.1	Business overview	254
13.1.6.2	Products offered	254
13.1.6.3	Recent developments	255
13.1.6.3.1	Product approvals	255
13.1.6.3.2	Expansions	255
13.1.7	BIOHM HEALTH INC.	256
13.1.7.1	Business overview	256
13.1.7.2	Products offered	256
13.1.7.3	Recent developments	258
13.1.7.3.1	Deals	258
13.1.8	ACTIAL FARMACEUTICA SRL	259
13.1.8.1	Business overview	259
13.1.8.2	Products offered	259
13.1.9	OPTIBIOTIX HEALTH PLC	260
13.1.9.1	Business overview	260
13.1.9.2	Products offered	261
13.1.9.3	Recent developments	262
13.1.9.3.1	Product approvals	262
13.1.9.3.2	Deals	262
13.1.10	RESBIOTIC	263
13.1.10.1	Business overview	263
13.1.10.2	Products offered	263
13.1.10.3	Recent developments	264
13.1.10.3.1	Expansions	264
?		
13.1.11	INFINANT HEALTH INC.	265
13.1.11.1	Business overview	265
13.1.11.2	Products offered	265
13.1.12	BIOGAIA AB	266
13.1.12.1	Business overview	266
13.1.12.2	Products offered	268
13.1.12.3	Recent developments	269
13.1.12.3.1	Deals	269
13.1.12.3.2	Expansions	269
13.1.13	EXEGI PHARMA, LLC	270
13.1.13.1	Business overview	270
13.1.13.2	Products offered	270

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.1.13.3	Recent developments	271
13.1.13.3.1	Deals	271
13.2	OTHER PLAYERS	272
13.2.1	AOBIOME	272
13.2.2	GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.	273
13.2.3	NUBIYOTA	274
13.2.4	OXTHERA AB	275
13.2.5	NEXBIOME	276
13.2.6	VEDANTA BIOSCIENCES, INC.	277
13.2.7	ENTEROME	278
13.2.8	APSEN FARMACEUTICA S.A.	279
13.2.9	METAGEN THERAPEUTICS, INC.	280
13.2.10	SNIPR BIOME	281
13.2.11	MAAT PHARMA SA	282
13.2.12	MIKROBIOMIK	283
14	APPENDIX	284
14.1	DISCUSSION GUIDE	284
14.2	KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL	287
14.3	CUSTOMIZATION OPTIONS	289
14.4	RELATED REPORTS	289
14.5	AUTHOR DETAILS	290

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2030

Market Report | 2024-09-17 | 291 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature